• Cancel
    Date：2021-11

    Exclusive Financial Advisor to BDG

  • Cancel
    Date：2021-11

    Exclusive Financial Advisor to Longwood Valley

  • Cancel
    Date：2021-10

    Exclusive Financial Advisor to Bio-Bank Corp.

  • Cancel
    Date：2021-10

    Exclusive Financial Advisor to BIOLIGO

  • Cancel
    Date：2021-10

    Exclusive Financial Advisor to DataMesh

  • Cancel
    Date：2021-09

    Exclusive Financial Advisor to PEAK

  • Cancel
    Date：2021-09

    Exclusive Financial Advisor to Xinyi Semi

  • Cancel
    Date：2021-08

    Exclusive Financial Advisor to OrbusNeich

  • Cancel
    Date：2021-08
    http://www.ceccapitalgroup.com/index.php?a=shows&catid=34&id=593

    Hangzhou, China, August 27, 2021 - Lynk Pharmaceuticals CO., LTD (hereinafter referred to as “Lynk Pharmaceuticals”), an innovative pharmaceutical R&D company, today announced that it has successfully completed Series B financing of $50 million, with Lilly Asia Ventures (LAV) as lead investor, New Alliance Capital and Hangzhou HEDA Biological Medicine Venture Capital Partnership (L.L.P.) as co-investors, and its original shareholders Legend Capital and Med-Fine Capital as participating investors. The proceeds from this round of financing will mainly be used to conduct Phase I and II clinical trials for multiple programs in the R&D pipeline of Lynk Pharmaceuticals. In addition, the funding will be used to expand international business, strengthen international collaborations with leading companies and support preclinical development of new projects. CEC Capital acted as the exclusive financial advisor to Lynk Pharmaceuticals in this transaction.